Overview

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer

Status:
Active, not recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
This research study is studying an investigational drug as a possible treatment for breast cancer that is positive for the protein Human Epidermal Growth Factor Receptor 2, also known as HER2-positive breast cancer. The drug involved in this study is: -ado-trastuzumab emtansine (T-DM1)
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Gateway for Cancer Research
Susan G. Komen Breast Cancer Foundation
Treatments:
Ado-Trastuzumab Emtansine
Trastuzumab